Prospective clinical study of arsenic agent combined with chemotherapy in the treatment of acute myeloid leukemia with high EVI1 expression

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054243

Enrollment

Unknown

Registered

2021-12-11

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

Experimental group:Arsenic treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: AML was confirmed according to WHO (2016) diagnostic criteria, and was identified as a newly diagnosed patient with high EVI1 expression by RT-PCR.

Exclusion criteria

Exclusion criteria: 1. Organ dysfunction; 2. Patients who are not suitable for chemotherapy.

Design outcomes

Primary

Measure	Time frame
Complete response rate;RFS (Relapse-Free Survival);OS (Overall Survival);	—

Countries

China

Contacts

Public ContactXie Shuangfeng

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

xiesf@163.com+86 13710693747

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026